Spontaneously immortalised bovine mammary epithelial cells exhibit a distinct gene expression pattern from the breast cancer cells

Chenfu Zhao†, Lu Meng†, Hongyu Hu, Xudong Wang, Fangyu Shi, Yajuan Wang, Qianqian Li, Aixing Lin*

Abstract

Background: Spontaneous immortalisation of cultured mammary epithelial cells (MECs) is an extremely rare event, and the molecular mechanism behind spontaneous immortalisation of MECs is unclear. Here, we report the establishment of a spontaneously immortalised bovine mammary epithelial cell line (BME65Cs) and the changes in gene expression associated with BME65Cs cells.

Results: BME65Cs cells maintain the general characteristics of normal mammary epithelial cells in morphology, karyotype and immunohistochemistry, and are accompanied by the activation of endogenous bTERT (bovine Telomerase Reverse Transcriptase) and stabilisation of the telomere. Currently, BME65Cs cells have been passed for more than 220 generations, and these cells exhibit non-malignant transformation. The expression of multiple genes was investigated in BME65Cs cells, senescent BMECs (bovine MECs) cells, early passage BMECs cells and MCF-7 cells (a human breast cancer cell line). In comparison with early passage BMECs cells, the expression of senescence-relevant apoptosis-related gene were significantly changed in BME65Cs cells. P16INK4a was downregulated, p53 was low expressed and Bax/Bcl-2 ratio was reversed. Moreover, a slight upregulation of the oncogene c-Myc, along with an undetectable level of breast tumor-related gene Bag-1 and TRPS-1, was observed in BME65Cs cells while these genes are all highly expressed in MCF-7. In addition, DNMT1 is upregulated in BME65Cs. These results suggest that the inhibition of both senescence and mitochondrial apoptosis signalling pathways contribute to the immortality of BME65Cs cells. The expression of p53 and p16INK4a in BME65Cs was altered in the pattern of down-regulation but not "loss", suggesting that this spontaneous immortalization is possibly initiated by other mechanism rather than gene mutation of p53 or p16INK4a.

Conclusions: Spontaneously immortalised BME65Cs cells maintain many characteristics of normal BMECs cells and exhibit non-malignant transformation. Although this cell line displays altered patterns of gene expression, it is clearly distinct from malignant breast cancer cell line. It showed that co-inhibition of cellular senescence and mitochondrial apoptosis pathways coordinates BME65Cs cells immortalisation. Additionally, mechanisms other than gene mutation are likely to be involved in regulation of cellular functions. This study provides an insight into the relationship between cell senescence and immortalisation. BME65Cs cells will be useful in future studies of cellular senescence and tumorigenesis.

Background

In serum-free culture, primary mammary epithelial cells (MECs) proliferate for 10 ± 20 population doublings (PD), after which they enter the first growth barrier: self-selection or M0 also named stasis [1]. Thereafter, small cells can appear, and these cells proliferate for up to 40-50 PD, after which they enter the second growth barrier: replicative senescence or M1, also called "ago-nescence" [2]. There are few reports of mammary epithelial cells (especially bovine MECs) spontaneously overcoming proliferative barriers and leading to immortalization [3].
Immortalisation is a process where cultured cells escape senescence and acquire the ability to grow in culture indefinitely [4]. Whether changes in gene expression accompany the spontaneous immortalisation of MECs is unclear, relevant data are available from cancer cells. It has been known that cellular replicative senescence is triggered by telomere shortening during each cell division [5]. Telomerase reverse transcriptase (TERT) maintains telomere length by replicating the telomere tracts and preventing cells from replicative senescence [6]. Overexpression of TERT has been used to immortalize a variety of normal diploid cell strains [7]. In addition, TERT gene has frequently been activated in cancer and stem cells [5,8]. The tumor suppressor p53, which is inactivated in numerous cancer cells due to its gene mutation [9,10], plays a key role in repressing transcription of TERT gene [11]. Another important tumor suppressor p16INK4a, a cyclin-dependent kinase (CDK) inhibitor, maintains normal cellular properties by preventing both centrosome dysfunction and genomic instability [12]. In mammary epithelial cells, it has been suggested that the pre-reduction of p16INK4a by a direct or indirect method is required for TERT-mediated immortalisation [4]. In addition to the negative regulation of p16INK4a and p53 in the control of cell proliferation, some proto-oncogene such as c-Myc and others may help cells to escape senescence control and lead to carcinogenesis [11,13,14]. However, it is unclear whether the expression patterns of these cellular oncogenes and tumor suppressors are altered in immortalized cells and what is the mechanism for spontaneous immortalization of MECs.

Immortalised bovine mammary epithelial cell line can be used as an in vitro screening system to identify superior transgenes, and to improve genomic modification technological research, thereby improving the efficiency of transgenic animal production [15]. In this study, we described a spontaneously immortalised cell line (BME65Cs) derived from serial passages of bovine mammary epithelial cells. We performed a detailed investigation of cell characteristics and changes in gene expression in comparison to early passage cells, senescent cells and human mammary cancer cells (MCF-7). Our data showed that multiple signal pathways are involved in this process and BME65Cs is distinct from malignant MCF-7 in cancer associated gene expression.

Results

Spontaneously immortalised BME65Cs cells maintain the normal morphology and proliferation characteristic of normal BMECs

The spontaneously immortalised BME65Cs cell line was established from in vitro cell culture. The initial cell focus was observed in a culture of BMECs cells when normal cells had entered the senescence state. This cell focus had a similar morphology to the early passage BMECs cells (Figure 1A) and was surrounded by an annulus of senescent cells (Figure 1C). In serum-containing culture, normal BMECs cells enter replicative senescence at PDL 34 (Figure 1B), whereas BME65Cs cells have been passed more than PDL 220. Continuous observation showed that before PDL 55 BME65Cs had a doubling time of approximately 48 hours, which was similar to normal cells. At PDL 55, although some of these cells become longer and less proliferative, a majority of cells remained epithelial morphology with a doubling time of approximately 72 hours (Figure 1D). This observation is consistent with the growth rate assay (Figure 1E and 1F). There was an adjustment phase required for BME65Cs cells to become a stable cell line. Interestingly, a small proportion of cells died in each passage.

BME65Cs cells maintain many characteristics of normal mammary epithelial cells

The breast epithelial compartment comprises two distinct lineages: the luminal epithelial and the myoepithelial lineage. It has been suggested that in vitro, normal luminal epithelial cells from the human mammary gland immunostain for CK18 (mammary epithelial cell specific marker protein cytokeratin 18), ESA (epithelial specific antigen) and MUC-2 (mucin 2 glycoprotein) [16], whereas myoepithelial cells are CK18+/ESA-/MUC- [16,17]. To test if BME65Cs cells are originated from the luminal epithelial or from myoepithelial, BME65Cs cells were immunostained with these three antibodies. The results showed that BME65Cs are CK18+/ESA-/MUC+ in accordance with normal BMECs. Moreover, BME65Cs, similar to normal BMEC, showed a very slight signal in the staining of CK14, a maker of myoepithelial cells [1] (Figure 2).

Cell cycle and apoptosis are very important functional parameters used to assess cellular metabolism and physiology. We determined the cell cycle distribution of BME65Cs, early passage (PDL 12) and late passage (PDL 28) BMECs by flow cytometry. As shown in Figure 3A, growth arrest in the G0/G1 and G2/M phases was observed in late BMECs, but not in BME65Cs and early passage BMECs. Moreover, the proportion of cells in the S phase was increased in BME65Cs cells (PDL 102), but significantly decreased in late passage cells compared to early passage BMECs cells, suggesting that BME65Cs cell line has a higher proliferative capacity than that of normal cells.

To identify senescent state, a senescence marker, senescence-associated β-galactosidase (SA-β-gal), was examined in BME65Cs (PDL 87) as well as the control BMECs (PDL 28 and PDL 7). SA-β-gal staining was
Figure 1 Cell morphology and cell growth rate of BME65Cs cells. 

A. Phase-contrast images of in vitro cultivated, early passage BMECs cells (PDL 10) with typical morphologies. 

B. Senescent BMECs cells (PDL 34) with an increased size. 

C. The initially isolated population of immortalised epithelial-like cells (BME65Cs). 

D. BME65Cs cells (PDL 120) with the typical cobblestone pattern of freshly isolated primary BMECs cells. Bars: 50 μm. 

E. Growth curve of BME65Cs and BMECs cells. To determine growth rates, primary (PDL 2) and immortal mammary epithelial cells (PDL 41) were plated at a density of $3 \times 10^5$ cells/10 cm dish using culture conditions as described above. At 80% confluency, cells were trypsinised and subcultured every two days, and cumulative population doublings based on cell numbers was calculated. Normal BMECs cells entered the senescent state at PDL 34, and spontaneously immortalised BME65Cs colonies were generated at this stage. 

F. Growth rates of primary BMECs cells (PDL 5) and immortal BME65Cs cells (PDL 120). Cells were plated at a density of $1 \times 10^5$ cells/10 cm dish for over 6 days of continuous culture, and cell numbers were counted each day. A similar increase in growth rate was observed between early passage MECs and immortalised BME65Cs cells.
observed in late passage BMECs cells (PDL 28) and was not observed in early passage BMECs cells (PDL 7). As expected, approximately 10% of BME65Cs cells (PDL 87) stained for SA-β-gal (Figure 3B), consistent with the culture observation. This suggests that some of the immortalised BME65Cs cells still undergo senescence in normal culture conditions.

The growth of BME65Cs cells in serum-containing medium is dependent on the supplementation of insulin, epidermal growth factor and hydrocortisone, displaying normal BMECs cell growth characteristics. In comparison, the breast cancer cell line MCF-7 and the previously reported OMEC II (ovine immortal MECs) grow very rapidly in serum-containing medium without any further additives [18]. To determine whether immortalised BME65Cs cells have cancer cell potential, the soft agar assay for colony formation was performed. No colony was formed in BME65Cs (PDL 110) and normal BMECs (PDL 20), while obvious colony formation in MCF-7 is obvious (Figure 4A). Furthermore, the cell-cell contact in BME65Cs cells induced growth arrest (data not shown). These results together suggested that BME65Cs cells had a normal growth characteristic of anchor dependency and no tendency for malignant transformation [19].

To understand the cytogenetic property of the BME65Cs cell line, twenty-one metaphase spreads of PDL 110 were examined. Nineteen of them maintained normal female karyotype (60, XX), and only two cells appeared abnormal with 61, XX karyotype (Figure 4B). This differed from OMEC II, in which 3-4% of the cells were heteroploid at an earlier stage (PDL 5) and 25% at passage 60 [18]. Thus, the karyotype analysis indicated that the BME65Cs cell line has stable cytogenetic properties.

Telomere length was stabilised without further elongation in BME65Cs cells

*TERT* expression is thought to be an important factor for cellular immortalization [20]. To confirm whether endogenous *bTERT* is activated during immortalisation of BME65Cs cells, the expression of *bTERT* mRNA was
detected by RT-PCR. As expected, bTERT was obviously transcribed in BME65Cs cells (PDL 104) but silenced in control BMECs cells (PDL 5 and 22) (Figure 5A).

Next, telomere lengths were further assayed by southern hybridisation. The mean telomere length of terminal restriction fragments (TRFs) in BME65Cs cells (PDL 104) is 18.7 kb. Comparatively, TRFs in BMECs cells at PDL 5 and PDL 22 are 17.9 and 6.4 kb, respectively (Figure 5B). This result suggests that telomere length is maintained in the BME65Cs cell line.

**Gene expression profile was changed in BME65Cs cells**

Cells that undergo immortalisation escape the controls of senescence and apoptosis. In order to gain insight into possible pathways involved in the BME65Cs cell line immortalisation, we selected 34 genes regulated mainly at the level of transcription to investigate the differences in gene expression between BME65Cs cells, senescent BMECs cells and early passage BMECs cells, as well as the MCF-7 cell line. Analysis of transcription profiles indicated that transcription levels of several genes, which are important for cell survival and growth, are significantly altered in BME65Cs comparing to the early passage BMECs (Figure 6).

It is well known that p16INK4a and p53 are important for cellular apoptosis and senescence. Thus, we initially examined changes in expression of these two genes. Both p16INK4a and p53 are significantly changed (8 fold decrease) in BME65Cs cells, indicating the importance of p16INK4a and p53 signalling pathways in immortalisation of the BME65Cs cell line. Moreover, in senescent BMECs cells the expression of p16INK4a was unchanged, but there was a slight change in p53 (2 fold decrease), suggesting there is no correlation between the
expression of p53 and p16\textsuperscript{INK4a}. In MCF-7 cells, expression of both genes is undetectable (Row2-3 in Figure 6). As the p53 protein is frequently absent in cancer cells [9,10], we investigated p21\textsuperscript{cip1}, one of the downstream targets of p53 that functions in cell cycle regulation [21], to enhance the result of p53. Paralleling the expression of p53, an undetectable signal of p21\textsuperscript{cip1} was observed in both BME65Cs cells and MCF-7 cells, whereas a slight change (0.75 fold decrease) was observed in senescent cells (Row 4).

Next, we examined Bcl-2 family genes. Bcl-2 and Bax act crucial roles in the mitochondrial apoptosis pathway by suppressing and improving apoptotic cell death, respectively [22-25]. Expression of Bcl-2 mRNA was unchanged in BME65Cs cells and was slightly downregulated (0.75-fold) in senescent BMECs cells compared to early passaged BMECs cells, whereas expression of Bcl-2 was significantly lower (0.25 fold) in MCF-7 cells (Row 5). Bax mRNA was upregulated (2.5 fold) in senescent BMECs cells and downregulated (4 fold) in MCF-7 cells. Notably, Bax mRNA was not detected in BME65Cs cells (Row 6). Moreover, expression of another anti-apoptotic Bcl-2 family gene, Bag-1 [26], was unchanged in the three non-cancer cells. As shown, Bag-1 was undetectable in early passaged cells, senescent BMECs cells and BME65Cs cells, whereas there was high expression in MCF-7 cells (Row 7). Thus, the expression of Bcl-2, Bax and Bag-1 in BME65Cs cells was different from expression in MCF-7 cells. These results suggest that the immortalisation of the BME65Cs line involved inhibition of the mitochondrial apoptosis pathway.

To further understand the difference between spontaneously immortalised MECs and breast cancer cells, we

![Figure 4 Soft agar assay and karyotype analysis in immortal BME65s cells and early passage BMECs cells. A) Analysis of colony formation used for evaluating malignant potential by the soft agar assay. Colonies containing more than ten viable cells were scored positive. Obvious colony formation was shown in MCF-7 cells, which served as a positive control. Bars: 50 μm. B) Comparison of chromosome numbers. At least 20 well-spread metaphase chromosomes from immortal BME65Cs cells (passage 110) and BMECs cells (primary passage16) were examined and the characteristic patterns illustrated were observed.](image-url)
investigated the expression of other genes considered to be differentially expressed or highly expressed in breast cancer cells. Two genes, TRPS-1 and c-Myc [27,14], displayed the difference. TRPS-1 expression was undetectable in both BME65Cs cells and early passage BMECs cells, which significantly distinguished from the high expression in MCF-7 cells. However, a low expression of TRPS-1 was shown in senescent cells (Row 8). Similarly, expression of c-Myc was almost undetectable in early passage and senescent BMECs cells. Although a low level of expression was detected in BME65Cs cells, by contrast, c-Myc was highly expressed in MCF-7 cells, about 200 fold higher than in BME65Cs cells (Row 9). Therefore, in addition to Bag-1, the expression level of c-Myc and TRPS-1 in BME65Cs cells was also markedly different from that in MCF-7 cells.

To understand the possible changes of DNA methylation that may cause altered gene expression in BME65Cs cells, we examined three DNA methyltransferases genes: DNMT1, DNMT2 and DNMT3. A significant difference was found for DNMT1. As shown, DNMT1 mRNA was upregulated in BME65Cs cells (3 fold), MCF-7 cells (4 fold) and senescent cells (2 fold). DNMT1 (DNA methyltransferase 1) is primarily a maintenance methylase, which reproduces DNA methylation patterns from hemimethylated DNA during cell division [28]. DNMT1 protein is disproportionately overexpressed in the S-phase fraction of estrogen receptor-negative cancer cell lines, including the MCF-7 line [29]. Thus, the upregulation of DNMT1 in the BME65Cs cell line suggests a possible change in DNA methylation.

**Discussion**

We have established a spontaneously immortalised mammary epithelial cell line, BME65Cs. This cell line exhibits the majority of normal MECs features, whereas growth character, the ability to form colonies and expression of relevant breast tumor genes are significantly different from breast cancer cells (MCF-7). These data suggest that BME65Cs cells are not derived from malignant transformations. Whether or not in vitro spontaneous transformation is correlated with in vivo benign tumor transformation, the immortal BME65Cs cell line will be a useful tool for studying the molecular mechanism of tumorigenesis and cellular senescence. In contrast, TERT or SV40 gene mediated immortalization by the random integration of exogenous genes may bring an unforeseeable influence on natural gene expression and regulation.

There are three types of human mammary epithelial cell progenitors have been identified. The first is thought to be a luminal-restricted progenitor; the second type is a bipotent progenitor which is identified by its ability to produce “mixed”colonies in single cell

![Figure 5 Detection of bTERT expression and analysis of telomere length in BME65Cs and BMECs cells.](image-url)
assays; the third type of progenitor is thought to be myoepithelial restricted progenitor because it only produces cells with myoepithelial features [30]. In this study, a part of normal cultured BMECs show a basal (myoepithelial) markers (CK14+) coinciding with the observation in human MECs [1]. However, BME65Cs show a MUC+/ESA+ CK14- and no "mixed" population are found, which suggests BME65Cs is not derived from myoepithelial cell or bipotent progenitor. Although BME65Cs maintains many characters of luminal cells with stable proliferation behaviour over the long period of culture, it is unclear whether BME65Cs derived from a luminal epithelial lineage or from a progenitor cell with the capacity for luminal.

Transcriptional analysis of multiple genes sheds light on the number of genes involved in the immortalisation of BME65Cs cells. An interesting question raised by the data is the following: what are the main factors that contribute to initiation of the BME65Cs cells immortalisation? There are two signaling pathways, p16INK4a-pRb and p53-p21, that are mainly responsible for the control of cellular senescence [12,31]. The tumor suppressor

---

**Figure 6** Relative genes expression of early passage senescent BMECs, BME65Cs and MCF-7 cells. **A** The detection of relative genes expression by RT-PCR. **B** Analysis of expression level by gray scale. The expression level of each gene in BMECs cells (PDL 14) was set to 1.0. The expression level for TRPS-1, Bag-1 and c-Myc in MCF-7 cells was set to 1.0 because these three genes expressions were not detected in BMECs cells (PDL 14). Other samples were adjusted accordingly. All PCR products were confirmed by sequencing. Gray scale analysis is from at least 3 independent experiments. *: P < 0.05 compared to BMECs cells passage 14 (Student’s t-test). **: P < 0.01 compared to BMECs cells passage 14 (Student’s t-test).
genes $p16^{INK4a}$ and $p53$ are frequently inactivated in cancer cells; inhibition of them escapes cellular senescence leading to tumorigenesis [31,32]. In this study, a significant change (but not loss) of $p16^{INK4a}$ and $p53$ were found in BME65Cs cells, suggesting that the inhibition of senescent-relevant pathways contributes to the BME65Cs cell line immortalisation. Additionally, the $p16^{INK4a}$-pRb pathway is thought to control the first growth barrier (self-selection) of MECs [1], and downregulation of $p16^{INK4a}$ is required for the TERT-mediated immortalisation of MECs [4]. Therefore, downregulation of $p16^{INK4a}$ is likely to be one of the key factors associating to BME65Cs cells immortalisation. However, there is no evidence suggesting that inactivation or downregulation of $p16^{INK4a}$ alone can induce immortalisation of MECs. Thus, changes in expression of other genes may also be involved in the initiation of BME65Cs cells immortalisation. Although the absence of $p53$ is thought to be an important initial factor for numbers of cancers, and several genes in the Bcl-2 family are regulated by $p53$ [9,24,31], it is unclear what the cause for the shortage of $p53$ expression (compare to normal cell) in BME65Cs cells. It has been known that telomere shortening and DNA damage activate $p53$ expression [21,24]. Thus, the maintenance of telomere length in BME65Cs cells may be the one reason for low expression level of $p53$. There remains a discrepancy between the relationship of $p53$ and $p16^{INK4a}$. In most cancer cells, $p16^{INK4a}$ and $p53$ are two-independent signalling pathways [33]. However, one report suggests that $p16^{INK4a}$ regulates $p53$ in human mammary epithelial cells [34]. Despite this, the low expression of $p53$ might contribute to the coordination of BME65Cs cells immortalisation, because $p53$ plays a role in transcriptional repression of TERT [11]. Together, we speculate that the low expression of both $p16^{INK4a}$ and $p53$ is important for the maintenance of BME65Cs cells immortalisation.

Overexpression of TERT protects telomere repeats from erosion and, consequently, from induction of replicative senescence or apoptosis [35]. Thus, expression of $bTERT$ may be another important factor for immortalisation of BME65Cs cells. TERT is positively regulated by c-Myc [36], but negatively regulated by $p53$ [11]. Therefore, the low expression of $p53$ and upregulation of c-Myc in BME65Cs cells might contribute to the activation of $bTERT$, and expression of $bTERT$ may subsequently lead to stable telomere length in BME65Cs cells, aiding cells in overcoming senescence and leading to immortalisation. As a transcriptional factor, c-Myc is believed to regulate the expression of 15% of all genes, including genes involved in cell division, cell growth, and apoptosis [37]. In addition to the high expression in a number of cancer cells, c-Myc is also expressed in stem cells, and is thought to be a requirement for the maintenance of stemness [38]. Hence, we presume that the function pattern of cell lineage-specific regulation of c-Myc might be dependent on its expression level. Curiously, the detection of TRL length shows discontinuity in BME65Cs. We suppose that it might be due to some non-immortal cells existing in BME65Cs, since some BME65Cs still died in each passage and showed SA-β-gal positive. It is interest to point out that the telomere length in BME65Cs is similar to that in early passage BMECs, this suggests immortalisation event for BME65Cs might occur in early passage cell.

In addition to c-Myc, two other genes, TRPS-1 and Bag-1, are also highly expressed in MCF-7 cells but undetectable in BME65Cs cells. TRPS-1 is called tricho-rhino-phalangeal syndromes type 1 gene, which mutations are previously shown to be associated with three rare autosomal dominant genetic disorders known as the tricho-rhino-phalangeal syndromes (TRPS). Recently, TRPS-1 protein has been found to be dramatically overexpressed in >90% of early and late-stage breast cancers [27]. Bag-1 is a multifunctional protein that interacts with a wide range of cellular targets and regulates cell survival, signaling, metastasis, proliferation and transcription [26,39]. In breast cancer, overexpression of Bag-1 has been detected in a majority of cases [40]. Taken together, the expression of TRPS-1 and Bag-1 may be used to evaluate malignant or non-malignant transformation of immortalised MECs. However, low expression of TRPS-1 was detected in senescent BMECs cells, implying that expression of TRPS-1 could be regulated by the cellular growth state, and TRPS-1 protein probably has other function that differs from its function in cancer cells.

Bcl-2 and Bax are important oncoproteins involved in regulation of cellular apoptosis via the mitochondrial apoptosis pathway. Bcl-2 functions in suppressing cell apoptosis, whereas Bax promotes cell apoptosis [23,41]. Paradoxically, expression of Bcl-2 has been consistently associated with a better prognosis of breast cancer patients [41-43]. It has been suggested that the Bax/Bcl-2 ratio determines whether apoptosis will occur [24]. In this study, Bax is deficient in BME65Cs cells, whereas Bcl-2 is highly expressed. Hence, immortalisation of BME65Cs cells is also accompanied by the inhibition of the mitochondrial apoptosis pathway. Interestingly, expression of another member of the Bcl-2 family, Bag-1, is undetectable in three different bovine MECs including BME65Cs cells and excluding MCF-7 cells.

Although we have analysed changes in expression of several genes from different cell strains, it is unclear what the initial mechanism is responsible for the change of these genes. Based on the fact that both $p16^{INK4a}$ and $p53$ are low expressed but not silenced in BME65Cs...
cells, we propose that these two genes are not mutated during immortalisation. In addition, epigenetic control is another important mechanism in regulation of genes expression. Abnormal DNA methylation patterns have been shown in a number of cancer cells [44]. Overexpression of DNMT1 has been detected in several human cancers [45-47]. Carcinogenesis is often accompanied by increases of DNMT1 mRNA, DNMT1 protein, and DNA methyltransferase activity [48-50]. Moreover, epigenetic change has been shown the important role in immortalisation of human MECs [51,52]. In this study, DNMT1 is significantly increased in BME65Cs cells and highly expressed in MCF-7 cells, suggesting that DNA methylation status is likely to be linked to immortalisation. Whether the epigenetic changes conclusively lead to the altered expression of “immortalisation-initial genes” in BME65Cs cells requires further investigation.

Conclusions

During the spontaneous immortalisation of mammary epithelial cells, BME65Cs cells undergo changes in gene expression. These changes improve cellular proliferation and may not contribute to malignant potential. The bTERT activation accompanied by the alternation of gene expression in multi-pathways contributes to BME65Cs immortalisation. In addition, changes in expression of immortalisation-related genes are likely to be controlled by some mechanisms other than gene mutation, such as DNA methylation. This study provides an insight into the relationship between cellular senescence and immortalisation. However, more research is required to provide a more detailed mechanism for the initiation of BME65Cs cells immortalisation. Regardless, this spontaneous immortal cell line will be a useful tool for studying cell molecular biology, in addition to the investigation of mammary gland specific expression and somatic gene targeting technology.

Methods

Cell culture

Mammary gland tissues were obtained from a normal two-year old Chinese Holstein dairy cattle in lactation period by surgical operation. Several small pieces of tissue were carefully dissected from the inner part of the large mammary gland tissue, and enzymatically digested by a combination of trypsin, hyaluronidase (sigma) and collagenase (sigma) to separate breast epithelial and ductal tissue from stromal cellular components. Cells were plated in serum-containing medium: DMEM-F12 supplemented with 10% iron-supplemented fetal cattle serum, 5 μg of insulin per ml, 10 ng of epidermal growth factor per ml, 0.5 μg of hydrocortisone per ml, and 100 units/ml penicillin and streptomycin. Digested cells were cultured at 37°C in a CO₂ incubator. The primary BMECs cells were passaged at a 1:8 split, and thus each passage represented three population doublings. Population doublings (PD) were calculated by the following equation: PD = [ln (split ratio)/ln2]. The population doubling level (PDL) resulted as the cumulative PD. BMECs cells displaying typical cobblestone morphology were subcultured at or near confluence, and the cumulative PDL was recorded. Immortalised BME65Cs cells were derived from cultured cell over PDL 34 and continuously cultured in the same medium. MCF-7 cells were cultured in DMEM medium supplemented with 10% iron-supplemented fetal cattle serum.

Cell growth assay

To determine growth rates, primary and immortal mammary epithelial cells (PDL 41) were plated at a density of 3 × 10⁵ cells/10 cm dish using culture conditions as described above. At 80% confluency, cells were trypsinised and subcultured every two days, and cumulative population doublings based on cell numbers was calculated. Cell growth was also determined by plating cells at a density of 1 × 10⁵ cells/10 cm dish using conditions described above, and cells were counted each day for up to 6 days to determine cell numbers.

Indirect immunofluorescent staining

BMECs (PDL 12), BME65Cs (PDL 125) and fibroblast cells (PDL 10) were seeded in gelatin-coated chamber slides. Cells were fixed and permeabilised by addition of 3% paraformaldehyde for 30 minutes, followed by incubation with 0.3% Triton X-100 in PBS for 20 min. After blocking with 10% FCS in PBS, cells were incubated with the mouse anti-human cytokeratin 14 (CK14) antibody, the mouse anti-human cytokeratin 18 (CK18) antibody, the epithelial specific antigen (ESA) antibody and the mucin 2 glycoprotein monoclonal (MUC-2) antibody, respectively, followed by incubation with the secondary antibody (goat anti-mouse IgG-fluorescein isothiocyanate (FITC)-conjugated antibody, Sigma). Thereafter, 1.5 mM PI was added as a counterstain for immunofluorescence and incubated with cells in the dark for 5 minutes at room temperature. The mouse IgG3, IgG1 and IgG2a were used as isotype controls, respectively. Specific fluorescence was detected by using a laser confocal microscope.

Flow cytometric analysis

BMECs cells at PDL 12 and PDL 28, and BME65Cs cells (PDL 102) were plated at 10⁵ cells/well on 35mm plates in corresponding medium. Cultured cells were washed with PBS solution and trypsinised, then fixed in an ethanol (80%)/PBS solution at 4°C for 30 min. Thereafter, cells were incubated in a solution containing 0.2 mg/ml RNase at 37°C for 30 minutes and stained with 50 ng/ml
propidium iodide at room temperature for 30 minutes, and analysed by flow cytometry (FACScaliber; Becton Dickinson, San Jose, CA).

**Senescence-associated β-galactosidase assay (SA-β-gal)**

BMECs cells at PDL 7 and PDL 28, and BME65Cs cells (PDL 87) were washed with PBS and fixed for 5 minutes at room temperature with 3% formaldehyde. Subsequently, staining was performed with X-gal solution (1 mg/mL X-gal, 0.12 mM K₄Fe[CN]₆, 0.12 mM K₃Fe[CN]₆, 1 mM MgCl₂ in PBS at pH 6.0) for 12h at 37°C and then washed with PBS and photographed.

**Soft agar assay**

Soft agar assays were performed in duplicates using 300 cells/cm² as previously described [19]. MCF-7 cells were used as a positive control. The ability for anchorage-independent growth shown by clone formation was analysed after three weeks. Clones containing more than ten viable cells were scored as positive.

**Chromosomal analysis**

Metaphase chromosomes were prepared from BMECs cells (PDL 16) and BME65Cs cells (PDL 110), and grown on plastic plates. Logarithmically growing cells were arrested in metaphase using colcemid (sigma) (100 ng/ml), trypsinised, incubated for 30 minutes in 75 mM KCl, fixed with methanolacetic acid (3:1), dropped onto cold glass slides and stained with Giemsa (sigma). At least 20 well spread metaphases chromosomes from cultures were examined to obtain the characteristic patterns illustrated.

**Terminal restriction fragment (TRF) analysis**

The mean telomere length was evaluated by using TRF analysis, a variation of standard Southern analysis, and was quantified. Genomic DNA was extracted from BME65Cs cells (PDL 104), BMECs cells at PDL 5 and PDL 22. Two micrograms of DNA was digested with a Hinf I/Rsa I mixture (10 U each) and separated on a 0.6% agarose gel by electrophoresis. To ascertain that a comparable amount of DNA from individual cells was loaded in each lane, the gel was stained with ethidium bromide and examined by UV light. The gel was then depurinated for 15 min in 0.25 M HCl, denatured for 20-30 min in 0.4 M NaOH and transferred to a nylon membrane using 0.4 M NaOH as the transferring buffer. After rinsing in 2×SSC and neutralisation solution, hybridisation was performed overnight at 65°C using a specific biotinylated detection telomere probe, then washed twice (5 minutes each time) in 2×SSC/0.1% sodium dodecyl sulfate (SDS) at room temperature and one time for 15 minutes in 0.2×SSC/0.1% SDS. The Luminescence Detection Kit (Roche) was used to detect TRF DNA on Hyperfilm. The size (in kilobases) of the mean telomere length was determined by comparing the migration distance with fragments of known DNA markers.

**Real-time PCR measurements of relative mRNA levels**

mRNA was collected from early passage (BMECs PDL 14), senescent (BMECs PDL 32) and spontaneously immortalised (BME65Cs PDL 104) mammary epithelial cells, as well as MCF-7 cells. Total cellular RNAs were extracted with an RNA extraction kit (Tiangen Co.) and 5 μg of total RNA from each sample was used for reverse transcription. One microliter of reverse transcription product was used as template for PCR amplification. Relative quantification was evaluated by calculating the ratios of copy numbers between target genes and the reference β-actin gene (a housekeeping gene). Primer pairs used for the analysis are displayed in Table 1. Considering the mRNA and protein levels in eukaryotic cells

### Table 1 Primer pairs used in the real-time PCR experiments of gene expression profiles

| Gene  | Accession | Sense primer | Antisense primer | Product |
|-------|-----------|--------------|------------------|---------|
| bTERT | NM001046242 | TCACGGGTCAAGAGACGGCTGT | CCGGCTACAATGGAATGTT | 886 bp  |
| p16INK4a | XM868375 | GTGTSGATGAGTGGGGACAGG | ACCAGGTGTCCTGGAAGCG | 134 bp  |
| p53   | NM14201   | CGGAAACACCTTTAGACACAGT | GTAGCCATGGTCGCTGATTG | 304 bp  |
| p21Cip1 | NM001098958 | TCTACACCTCAAAACCGA | GCAAAAGGATGAAGAGGT | 331 bp  |
| TRPS-1 | NM014112* | GCCCTCTTTGGGTCTCGGA | CCCCTCTGCTTTGTTGAG | 384 bp  |
| Bcl-2 | XM586976 | GCCCTCTTTGGGTTGCGGA | TTAGAGACAGCCCCAGAG | 209 bp  |
| Bax   | NM173894 | AGTGGCGGCGGCGAAGAATG | TTCTCCAGAGTTGACGGC | 287 bp  |
| Bag-1 | NM001076291 | TGCCATCTGAGCTTGGTGAC | TGTCCTTGCTCTGCTTG | 376 bp  |
| c-Myc | AF519455 | GTCTGACACCATCGACACAA | AAACCTCTCTGCTCTGCT | 376 bp  |
| DNMT1 | NM126851 | CCGAGATTGGAAGTGA | GACACCTGCCCATTGCT | 392 bp  |

*TRPS-1 primer pairs were designed by comparing homologous sequences between the *Homo sapiens* and *Bos taurus* genome, because the cattle TRPS-1 sequence has not been reported.

All other primer sequences were cited from GenBank. Each pairs of primers span intron-extron boundaries.
are poorly correlated [53], genes with a high correlation between mRNA and protein shown in previous reports were selected for detection (data not shown).

Acknowledgements
This work was supported by the National Natural Science Foundation of China, Grant No. 30370726, partly supported by that of No.30570947 and the National High-Tech Research and Development Program of China (863 Program, Grant No. 2006AA02Z113). We strongly acknowledge the support of Stem Cell Research Center of Peking University health science center for Prof. Chunyan Zhou providing MCF-7 cell line, and strongly acknowledge Dr. Huang Suming from Department of Biochemistry & Molecular Biology, University of Florida for revising this manuscript.

Authors’ contributions
CZ performed the isolation of cells, cell culture, cell growth analysis, cell cycle analysis, soft agar assay, chromosomal analysis and RT-PCR analysis, and participated in conceiving and designing the study and drafted the manuscript. LM performed the telomere length analysis and assisted in cell culture and RT-PCR analysis. HY and YW performed the senescence-associated β-galactosidase assay and assisted in chromosomal analysis. XW and QL performed the immuno-histochemical studies with F.S. AL coordinated the study, and participated in conceiving and designing the study and helped draft the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 2 June 2010 Accepted: 22 October 2010
Published: 22 October 2010

References
1. Garbe JC, Bhattacharya S, Merchant B, Bassett E, Swisshelm K, Feiler HS, Woyobek, AJ, Stampfer MR. Molecular Distinctions Between Stasis and Telomere Attenuation Senescence Barriers Shown by Long-term Culture of Normal Human Mammary Epithelial Cells. Cancer Res 2006, 66:3397-3405.
2. Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, Tlsty TD. Establishment and characterization of a bovine mammary epithelial cell line with unique properties. In Vitro Cell Dev Biol Anim 1996, 32:138-148.
3. Kim H, Farris J, Christman SA, Kong BW, Foster LK, O’Grady SM, Foster DN. Events in the immortalizing process of primary human mammary epithelial cells by the catalytic subunit of human telomerase. Biochem 2002, 365:765-772.
4. Harley CB, Fletcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
5. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989, 340:337-337.
6. Chang MW, Gilliam J, Mayhofer C, Fortschegger K, Allinaer G, Marzan G, Katihe H, Voglauer R. Comparison of early passage, senescent and hTERT immortalized endothelial cells Experimental. Cell Research 2005, 309:121-136.
7. Kim NW, Piatyseg MA, Prowse KR, Kim NW, Piatyseg MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cell lines and cancer. Science 1994, 266:2011-2015.
8. Adhikari AS, Iwakuma T. Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications. Fukuoka Igaku Zasshi 2009, 100:217-228.
9. Sheahan S, Bellamy CO, Harland SN, Harrison DJ, Prost S. TGFbeta induces apoptosis and EMT in primary mouse hepatocytes independently of p33, p21 and Rb status. BMC Cancer 2008, 8:191-202.
10. Kanaya T, Kyo S, Harnada K, Takakura M, Kitagaya Y, Harada H, Inoue M. Aenodoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcript. Clin Cancer Res 2000, 6:1239-1247.
11. McDermott KM, Zhang J, Holst CR, Kozakiewicz BK, Singla V, Tlsty TD. p16INK4A prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol 2006, 4:e51.
12. Sun Y, Wu J, Wu SH, Thakur A, Bollig A, Huang Y, Liao DJ. Expression profile of microRNAs in c-Myc induced mouse mammary tumors. Breast Cancer Res Treat 2009, 118:185-196.
13. Reisman D, Elkind NB, Roy B, Beaman J, Rottier V. C-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ 1993, 4:57-65.
14. Lubo H, Palmer C. Transgenic animal bioreactors–where we are. Transgenic Res 2000, 9:301-304.
15. Smith GH, Chepko G. Mammary epithelial stem cells. Microscopy Res Techn 2001, 52:190-203.
16. Nakauchi T, Orikasa K, Takahashi K, Nakoh T, Chiba S, Ichihara T, Leid M, Maniatis T. Generation of transgenic mice bearing human mammary epithelial cells. Nature Biotechnology 1999, 17:875-879.
17. Nakamura TM, TeCh TR. Reversing time: origin of telomerase. Cell 1998, 92:587-590.
18. Lundeberg AS, Hahn WC, Gupta P, Weinberg RA. Genes involved in senescence and immortalization. Curr Opin Cell Biol 2000, 12:705-709.
19. Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007, 19:488-496.
20. Mitchell A. Apoptosis: Bax to Bak. Nat Rev Mol Cell Biol 2001, 2:6.
21. Woodward TA, Klinger PD, Genko PV, Wolfe JT. Barrett’s esophagus, apoptosis and cell cycle regulation: correlation of p53 with Bcl-2 and p21 protein expression. Anticancer Res 2000, 20:2427-2432.
22. McLean JE, Datan E, Matasov D, Zaken ZF. Lack of Bax prevents influenza virus-induced apoptosis and causes diminished viral replication. J Virol 2009, 83:8233-8246.
23. Townsend PA, Stephanou A, Packham G, Latchman DS. BAG-1: a multi-functional pro-survival molecule. Int J Biochem Cell Biol 2005, 37:251-257.
24. Radvanyi L, Singh-Sandhu D, Galilchon S, Lovitt C, Pedyczak A, Mallo G, Gish K, Kowk K, Hanna W, Zubovits J, Amres J, Venter D, Hakimi J, Shortreed J, Donovan M, Parrington M, Dunn P, Omen R, Tartaglia J, Bernsen NL. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci USA 2008, 105:11005-11010.
25. Bestor TH. Cloning of a mammalian DNA methyltransferase. Gene 1988, 74:8-12.
26. Dwyer J, Li H, Xu D, Liu JP. Oncogene expression in breast cancer cells. Anticancer Res 2009, 29:1285-1292.
27. Nakauchi T, Orikasa K, Takahashi K, Nakoh T, Chiba S, Ichihara T, Leid M, Maniatis T. Generation of transgenic mice bearing human mammary epithelial cells. Nature Biotechnology 1999, 17:875-879.
28. Stennink R, J, Ibraheem EM, Evansa, C. Epithelial progenitors in the normal human mammary gland. J Mammary Gland Biol Neoplasia 2005, 10:49-59.
29. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
30. Radvanyi L, Singh-Sandhu D, Galilchon S, Lovitt C, Pedyczak A, Mallo G, Gish K, Kowk K, Hanna W, Zubovits J, Amres J, Venter D, Hakimi J, Shortreed J, Donovan M, Parrington M, Dunn P, Omen R, Tartaglia J, Bernsen NL. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci USA 2008, 105:11005-11010.
31. More than just proliferation: MycSwitching and signaling at the telomere. Nature Rev Mol Cell Biol 2001, 2:458-460.
32. Sherr CJ. The INK4a/ARF network in tumour suppression. Nature Rev Mol Cell Biol 2002, 3:745-754.
33. Blackburn EH. Telomere attributes. Nature Rev Mol Cell Biol 2001, 2:458-460.
34. Wyrobek AJ, Stampfer MR. Expression of hTERT in normal human mammary epithelial cells. Breast Cancer Res Treat 2001, 75:63-72.
40. Yang X, Hao Y, Ding Z, Pater A, Tang SC: Differential expression of antiapoptotic gene BAG-1 in human breast normal and cancer cell lines and tissues. Clin Cancer Res 1999, 5:1816-1822.
41. Adams JM, Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281:1322-1326.
42. Thomadaki H, Takler M, Sciorlas A: Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett 2007, 247:48-55.
43. Trede D, Montanaro L, Ceccharelli C, Barbieri S, Cavrini G, Santini D, Taffurelli M, Derenzi M: Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast. Ann Oncol 2007, 18:1004-1014.
44. González-García I, Castells A: New insights into a controversial topic: the methylation-cancer connection. Gastroenterology 2007, 132:2069-2070.
45. Sun L, Hui AM, Kanai Y, Sakamoto M, Hirohashi S: Increased DNA methyltransferase expression is associated with an early stage of human hepatocarcinogenesis. Ann J Cancer Res 1997, 88:1165-1170.
46. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S: Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 2001, 33:561-568.
47. Kanai Y, Ushijima S, Kondo Y, Nakanishi Y, Hirohashi S: DNA methyltransferase expression and DNA methylation of CpG islands and pericentromeric satellite regions in human colorectal and stomach cancers. Int J Cancer 2001, 91:205-212.
48. Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR, Baylin SB: High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci USA 1991, 88:3470-3474.
49. Issa JP, Vertino PM, Wu J, Sazawal S, Celano P, Nelkin BD, Hamilton SR, Baylin SB: Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst 1993, 85:1235-1240.
50. Belinsky SA, Nikula KJ, Baylin SB, Issa JP: Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc Natl Acad Sci USA 1996, 93:4045-4050.
51. Hinselwood RA, Huschtscha LI, Melki J, Strizaker C, Abdipranoto A, Vissel B, Ravai T, Wells CA, Hume DA, Reddel RR, Clark SJ: Concordant Epigenetic Silencing of Transforming Growth Factor-B Signaling Pathway Genes Occurs Early in Breast Carcinogenesis. Cancer Res 2007, 67:11517-11527.
52. Nowak P, Jensen TJ, Carbe JC, Stumper MR, Futschik BW: Stepwise DNA Methylation Changes Are Linked to Escape from Defined Proliferation Barriers and Mammary Epithelial Cell Immortalization. Cancer Res 2009, 69:5251-5258.
53. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Watham M, Kourou-Mehr H, Bussey KJ, Lee J, Espina V, Munson PJ, Petricoin E III, Liotta LA, Weinstein JN: Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA 2003, 100:14229-14234.